NVO Novo Nordisk A/S

NYSE
$41.71

Novo Nordisk A/S (NVO) is expected to report earnings on November 5, 2026, during market hours. The consensus earnings estimate is $0.80 per share, and the stock has had a Post-Earnings Announcement Drift (PEAD) of -12.4% since its last earnings release on August 4, 2026.

Novo Nordisk A/S Beat Expectations, Raises Guidance
Tuesday, August 4, 2026 · 12:37 PM ET
Earnings Date
3rd Quarter, Sep 2026
Nov 5
Thursday · 12:35 PM ET
Earnings Whisper
-
vs $0.80
Rev est $11.26B
Volatility
Enter your expectations below to reveal the current volatility.
Trend Analysis
Expectation
Earnings
Price action
Signals
Score
Sentiment
Grade
Life Cycle
Call Analysis
Earnings-AVWAP $45.72

Sign in or subscribe to unlock sentiment, short interest, and technical indicators.

About Novo Nordisk A/S

Novo-Nordisk A/S is a healthcare company that is engaged in the discovery, development, manufacturing and marketing of pharmaceutical products. The Company has two business segments: diabetes care and biopharmaceuticals.

Sector

Healthcare

Industry

Drug Manufacturers / Major

Held By 1 ETFs, by dollar flow

Charts powered in part by Lightweight Charts™ by TradingView.